Vertex Strikes About $10 Billion Deal to Acquire Crinetics
Vertex Pharmaceuticals is making a large bet on endocrine disease. The company agreed to acquire Crinetics Pharmaceuticals in an all-cash deal valued at about $10 billion. The purchase adds a pipeline of treatments for hormone disorders to a business long anchored in cystic fibrosis, a franchise that still drives most...









